VIENNA – After nearly three days of partnering meetings and sessions touting the latest therapeutic advances such as cell and gene therapy and the microbiome, along with presentations depicting the unprecedented level of capital flowing into the sector, it would be easy to think the biopharma industry had reached optimal capacity. But as the BIO Europe Spring meeting came to a close Wednesday, Evotec AG CEO and Austria native Werner Lanthaler suggested that progress and innovation "aren't happening as fast as they should."